NO20041225L - Rekombinant anti-osteopontinantistoff og anvendelse derav - Google Patents

Rekombinant anti-osteopontinantistoff og anvendelse derav

Info

Publication number
NO20041225L
NO20041225L NO20041225A NO20041225A NO20041225L NO 20041225 L NO20041225 L NO 20041225L NO 20041225 A NO20041225 A NO 20041225A NO 20041225 A NO20041225 A NO 20041225A NO 20041225 L NO20041225 L NO 20041225L
Authority
NO
Norway
Prior art keywords
recombinant anti
osteopontin antibody
osteopontin
antibody
recombinant
Prior art date
Application number
NO20041225A
Other languages
English (en)
Inventor
Toshimitsu Uede
Shigeyuki Kon
Nobuchika Yamamoto
Hirofumi Higuchi
Masaharu Torikai
Yoshiyuki Tokieda
Toshihiro Nakashima
Hiroaki Maeda
Original Assignee
Immuno Biological Lab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Biological Lab Co Ltd filed Critical Immuno Biological Lab Co Ltd
Publication of NO20041225L publication Critical patent/NO20041225L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20041225A 2001-09-25 2004-03-23 Rekombinant anti-osteopontinantistoff og anvendelse derav NO20041225L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001290700 2001-09-25
PCT/JP2002/009868 WO2003027151A1 (fr) 2001-09-25 2002-09-25 Anticorps recombinant anti-osteopontine et son utilisation

Publications (1)

Publication Number Publication Date
NO20041225L true NO20041225L (no) 2004-05-25

Family

ID=19112969

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041225A NO20041225L (no) 2001-09-25 2004-03-23 Rekombinant anti-osteopontinantistoff og anvendelse derav

Country Status (16)

Country Link
US (1) US7241873B2 (no)
EP (1) EP1431310A4 (no)
JP (1) JPWO2003027151A1 (no)
KR (1) KR20040048899A (no)
CN (1) CN100352844C (no)
AU (1) AU2002332290B2 (no)
BR (1) BR0213078A (no)
CA (1) CA2461529A1 (no)
HK (1) HK1084127A1 (no)
HU (1) HUP0402049A3 (no)
MX (1) MXPA04002837A (no)
NO (1) NO20041225L (no)
NZ (1) NZ531818A (no)
PL (1) PL369446A1 (no)
RU (1) RU2305111C2 (no)
WO (1) WO2003027151A1 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100469793C (zh) * 2001-04-05 2009-03-18 株式会社免疫生物研究所 抗骨桥蛋白抗体及其用途
BR0213078A (pt) 2001-09-25 2004-11-23 Fujisawa Pharmaceutical Co Anticorpo recombinante anti-osteopontina e uso do mesmo
AU2003258127A1 (en) * 2002-08-06 2004-02-23 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
WO2004103403A1 (ja) * 2003-05-23 2004-12-02 Immuno-Biological Laboratories Co., Ltd. 免疫担当細胞活性化阻害剤およびその用途
EP2369348A1 (en) * 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarkers for Alzheimer's disease
CA2552425C (en) * 2004-02-27 2018-02-06 F. Hoffmann-La Roche Ag Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
DK1721162T3 (da) * 2004-02-27 2008-12-15 Hoffmann La Roche Fremgangsmåde til at bedömme rheumatoid arthritis ved at måle anti-CCP og serumamyloid A
CA2589860A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
WO2006116793A1 (en) * 2005-05-04 2006-11-09 Australian Stem Cell Centre Limited Selecting, culturing and creating lineage committed hematopoietic stem cells
MY185597A (en) * 2005-09-20 2021-05-24 Avantor Performance Mat Inc Vegetarian protein a preparation and methods thereof
BRPI0711229A2 (pt) * 2006-05-31 2013-01-08 Astellas Pharma Inc anticorpo humanizado da osteopontina anti-humana, polinucleotÍdeo, vetor de expressço, cÉlula hospedeita, mÉtodo para produzir um anticorpo humanizado de osteopontina anti-humana, fÁrmaco terapÊutico, mÉtodo para prevenir ou tratar doenÇa autoimune e uso do anticorpo humanizado de oesteopontina anti-humana
EP2075258B1 (en) * 2006-10-26 2012-06-20 Gene Techno Science Co., Ltd. Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same
KR101436578B1 (ko) 2007-03-30 2014-09-01 슈 생-쥐스땡 척추 측만증의 발병 위험성을 측정하는 방법, 척추 측만증에 걸린 대상자를 계층화하는 방법, 척추 측만증에 걸린 대상자에 있어서 고정기의 효능을 평가하는 방법, 및 이를 위한 키트
KR100894265B1 (ko) * 2007-06-05 2009-04-21 재단법인서울대학교산학협력재단 골형성 촉진 펩타이드를 함유하는 주입형 골재생재
US9040666B2 (en) * 2007-07-13 2015-05-26 Bac Ip B.V. Single-domain antigen-binding proteins that bind mammalian IgG
CA2709305C (en) * 2007-12-13 2017-03-07 The Curators Of The University Of Missouri Compositions and methods for early pregnancy diagnosis
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
EP2239323A4 (en) * 2008-01-11 2012-05-23 Chemo Sero Therapeut Res Inst HUMANIZED ANTI-INEGRINE 9 HUMAN ANTIBODY
AU2009238897B2 (en) * 2008-04-24 2015-03-19 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
CA2722466A1 (en) * 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
UY31861A (es) * 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
WO2010006060A2 (en) * 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
CA2753280C (en) 2009-02-23 2017-04-25 Gene Techno Science Co., Ltd. Anti-human .alpha.9 integrin antibody and use thereof
BRPI1012195A2 (pt) * 2009-05-01 2018-04-24 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR101809761B1 (ko) * 2009-09-24 2017-12-15 가부시키가이샤 진 테크노 사이언스 세포 외 기질 단백질의 아미노산 서열 ｒｇｄ에 특이적인 인간화된 항체 및 그의 용도
TW201119676A (en) * 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY33707A (es) * 2010-11-04 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103747801A (zh) 2011-05-27 2014-04-23 卡罗生物制药股份有限公司 抗emr1抗体
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
NZ707641A (en) 2012-11-01 2016-09-30 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
TW201512219A (zh) 2013-03-15 2015-04-01 Abbvie Inc 針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
AU2015300080B2 (en) * 2014-08-06 2021-04-01 Mach5 Therapeutics, Inc. New anti-human Igbeta antibody
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US10349259B2 (en) * 2016-09-23 2019-07-09 Apple Inc. Broadcasting a device state in a wireless communication network
EP4010369A4 (en) * 2019-08-09 2023-11-22 The Board of Trustees of the Leland Stanford Junior University THERAPEUTIC ANTIBODIES AGAINST OSTEOPONTIN
CN115558015B (zh) * 2022-10-12 2024-01-19 生工生物工程（上海）股份有限公司 一种从gst融合蛋白酶切后的产物中纯化无gst标签的目的蛋白的方法和产品

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171358A (en) * 1875-12-21 Improvement in machines for trimming and punching roofing-slates
US239400A (en) * 1881-03-29 Tobacco-fork
US125023A (en) * 1872-03-26 Improvement in sand dredging-machines
US1408113A (en) * 1921-01-28 1922-02-28 Mason Richard Colbert Well-measuring device
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0690132T3 (da) 1993-03-11 2004-04-13 Chemo Sero Therapeut Res Inst Monoklonalt anti-HIV-antistof
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
EP0705842A2 (en) 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Regulated genes by stimulation of chondrocytes with 1L-1beta
US6686444B2 (en) 1996-08-22 2004-02-03 Children's Medical Center Corporation Osteopontin derived chemotactic peptides and methods of use
WO1998008379A1 (en) 1996-08-27 1998-03-05 Dana-Farber Cancer Institute Methods for identifying modulators of cellular interactions mediated by osteopontin
WO1998056405A1 (en) 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin
EP1003570A1 (en) 1997-08-15 2000-05-31 Children's Medical Center Corporation Osteopontin coated surfaces and methods of use
EP0921189B1 (en) * 1997-11-14 2005-01-12 Sankyo Company Limited Transgenic animal allergy models and methods for their use
US6414219B1 (en) * 1998-06-30 2002-07-02 Rutgers, The State University Of New Jersey Osteopontin knock-out mouse and methods of use thereof
MXPA01010403A (es) 1999-04-15 2004-09-10 Childrens Medical Center Agentes quimiotacticos e inhibidores derivados de osteopontina y usos de los mismos.
EP1175223A2 (en) 1999-04-15 2002-01-30 Children's Medical Center Corporation Methods and compositions for modulating an immune response
EP1269196B1 (en) * 2000-03-23 2007-11-21 Glaxo Group Limited Method of screening for inhibitors of osteopontin
WO2002032940A2 (en) 2000-10-18 2002-04-25 Children's Medical Center Corporation Osteopontin-coated surfaces and methods of use
CN100469793C (zh) * 2001-04-05 2009-03-18 株式会社免疫生物研究所 抗骨桥蛋白抗体及其用途
US7384633B2 (en) 2001-07-19 2008-06-10 Judicial Foundation The Chemo-Sero-Therapeutic Res. Human type antihuman IgE receptor antibody and fragment
BR0213078A (pt) 2001-09-25 2004-11-23 Fujisawa Pharmaceutical Co Anticorpo recombinante anti-osteopontina e uso do mesmo
CA2468020A1 (en) 2001-11-21 2003-06-05 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods
CN103518888A (zh) * 2013-10-14 2014-01-22 李民庆 一种养心宁神茶配方

Also Published As

Publication number Publication date
US7241873B2 (en) 2007-07-10
WO2003027151A1 (fr) 2003-04-03
JPWO2003027151A1 (ja) 2005-01-06
CN1688604A (zh) 2005-10-26
NZ531818A (en) 2005-10-28
PL369446A1 (en) 2005-04-18
US20060002923A1 (en) 2006-01-05
HUP0402049A2 (hu) 2005-01-28
BR0213078A (pt) 2004-11-23
AU2002332290B2 (en) 2007-11-08
EP1431310A1 (en) 2004-06-23
HK1084127A1 (en) 2006-07-21
RU2305111C2 (ru) 2007-08-27
HUP0402049A3 (en) 2009-04-28
MXPA04002837A (es) 2005-11-04
KR20040048899A (ko) 2004-06-10
CA2461529A1 (en) 2003-04-03
EP1431310A4 (en) 2005-03-23
RU2004112540A (ru) 2005-04-20
CN100352844C (zh) 2007-12-05

Similar Documents

Publication Publication Date Title
NO20041225L (no) Rekombinant anti-osteopontinantistoff og anvendelse derav
CY2019022I1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
NO20034405D0 (no) Anti-ostepontin-antistoff og anvendelse derav
AU2002332290A1 (en) Recombinant anti-osteopontin antibody and use thereof
HUP0400284A3 (en) Recombinant tumor specific antibody and use thereof
DK1163271T3 (da) Rekombinant IL-18 antistoffer og deres anvendelse
NO20034396D0 (no) Rekombinante antistoff uttrykt sammen med GnTIII
NO20033418D0 (no) Immunregulatoriske antistoffer og anvendelse derav
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1711207T3 (da) Interferon-alpha-antistoffer og anvendelse heraf
DK1746375T3 (da) Oxygendrevet forbrændingssystem og anvendelser deraf
NO20033387D0 (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
NO20033456L (no) Modifiserte og stabiliserte GDF-propeptider og anvendelse derav
DE60124863D1 (de) Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
DK2662390T3 (da) Interferon alpha receptor 1-antistoffer og anvendelse heraf
AU2002244968A1 (en) Anti-osteopontin antibody and use thereof
DK1411064T3 (da) Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer
NO20034159D0 (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
DE50202730D1 (de) Substituierte isoindole und ihre verwendung
DE60205008D1 (de) Kettelverfahren und -vorrichtung
DE60219418T8 (de) Silanylphenole und -naphthole
EP1437367A4 (en) ANTIBODIES AND ITS USE
IS8914A (is) Mótefni sem blokka prótínið Cripto og notkun þeirra

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0

FC2A Withdrawal, rejection or dismissal of laid open patent application